Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.35 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8996674 | 0.96 | ADRA2A (0.36) | MEN1ALDH1A1HPGDKMT2AL3MBTL1 | |
| SCHEMBL8374637 | 0.93 | ADRA2A (0.38) | ALDH1A1CNR2PTGER1PTGER4PTGER3 | |
| SCHEMBL7993479 | 0.93 | ADRA2A (0.38) | ALDH1A1CNR2PTGER1PTGER4PTGER3 | |
| SCHEMBL8009084 | 0.93 | ADRA2A (0.38) | ALDH1A1CNR2PTGER1PTGER4PTGER3 | |
| SCHEMBL7610062 | 0.93 | ADRA2A (0.38) | ALDH1A1CNR2PTGER1PTGER4PTGER3 | |
| SCHEMBL7604999 | 0.81 | TSHR (0.33) | MEN1KMT2ACNR2PTGER1PTGER4 | |
| SCHEMBL7994402 | 0.80 | ACLY (0.33) | CNR2PTGER1PTGER4PTGER3 | |
| SCHEMBL7633126 | 0.80 | PTGER1 (0.39) | MEN1ALDH1A1HPGDKMT2AL3MBTL1 | |
| SCHEMBL8006375 | 0.78 | KDM4E (0.35) | ALDH1A1CNR2PTGER4 | |
| SCHEMBL8070923 | 0.77 | LMNA (0.36) | ALDH1A1L3MBTL1CNR2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5670507-A | Method for reversing multiple drug resistant phenotype | CELL THERAPEUTICS, INC. (US) | 1997-09-23 | — | — | US | claimed |
| EP-0719267-B1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | disclosed |
| US-5859018-A | ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; CARDIOVASCULAR DISORDERS | CELL THERAPEUTICS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5856331-A | LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR | CELL THERAPEUTICS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5837703-A | AUTOIMMUNE DISEASES, ARTHRITIS, CANCER, LEUKEMIA, MULTIPLE SCLEROSIS; ANTITUMOR AGENTS | CELL THERAPEUTICS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5824677-A | SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE | CELL THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5801181-A | Amino alcohol substituted cyclic compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5795898-A | ANTITUMOR, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS | CELL THERAPEUTICS, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5777117-A | ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE, CYTOTOXIC AGENTS; MICROBIOCIDES, FUNGICIDES | CELL THERAPEUTICS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5670507-A | Method for reversing multiple drug resistant phenotype | CELL THERAPEUTICS, INC. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| EP-0719267-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719267-A4 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 1996-02-16 | — | — | EP | disclosed |
| US-5470878-A | Cell signaling inhibitors | CELL THERAPEUTICS, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1995013808-A1 | METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION | CELL THERAPEUTICS, INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1994022863-A9 | SECOND MESSENGER CELL SIGNALING INHIBITORS | — | 1994-12-22 | — | — | WO | disclosed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |